entertainment -WSS

entertainment

author：fashion 2025-09-06 03:27:52 - browse：23341

Robert F. Kennedy Jr. said Tuesday that he will head up a panel on vaccine safety for Donald Trump.

The president-elect’s transition team spokeswoman later walked that back, saying that he is “exploring the possibility” of forming a panel on autism, but “no decisions have been made.”

Let’s hope Trump drops any idea of a vaccine panel headed by Kennedy. For more than a decade, Kennedy has promoted anti-vaccine propaganda completely unconnected to reality. If Kennedy’s panel leads to even a small decline in vaccine rates across the country, it will result in the waste of untold amounts of money and, in all likelihood, the preventable deaths of infants too young to be vaccinated.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Kaiser Permanente unions announce official strike date

focus

WSS

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Ionis has late

Did you have Obamacare on your GOP debate bingo card?

Biogen shutters digital health group, ends Apple study, in cost cutting move

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Virtual Event: March of the Biosimilars

leisure time

entertainment

focus

Medicare details structure of new drug price negotiation program

Asbestos, a deadly carcinogen, banned by EPA

Trump demands the U.S. pay no more for drugs than other countries … again

Shingles, which affected Dianne Feinstein, is on the rise

Duchenne breakthrough therapy leaves behind pioneering families

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Psychedelics group wrestles with new pharma identity

Physicians and social media: If you see something, say something?

Guidelines to prevent youth baseball injuries need more muscle

Intermittent fasting comes with a heart risk? Not so fast

Wikipedia

Data show record exodus of life scientists from academia

Gene editing the human germline: What are the risks?

5 to watch: Tech startups trying to solve health care's staffing crisis

AstraZeneca to buy developer of next

How one patient went off dialysis — and others can too

Researchers use wearables data and AI to predict preterm birth risk

focus

focus

hotspot

hotspot